3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
126
Cisplatin
48
Cetuximab
46
Nivolumab
36
Carboplatin
33
Paclitaxel
28
Fluorouracil
26
Docetaxel
17
Cyclophosphamide
12
avelumab
11
Radiotherapy
11
cemiplimab
10
atezolizumab
10
durvalumab
9
Ipilimumab
8
spartalizumab
7
fludarabine
7
budigalimab
7
Gemcitabine
7
Capecitabine
7
tremelimumab
6
lenvatinib
6
Pemetrexed
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Fulvestrant
5
zimberelimab
4
tislelizumab
4
Trastuzumab
4
Oxaliplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Squamous Cell Carcinoma of Head and Neck
×
STX-478
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled